Shuttle Pharma’s recent highlights include the following: Received FDA approval to proceed with the Phase 2 Clinical Trial of Ropidoxuridine for treatment of patients with glioblastoma; Received central institutional review board approval for the Phase 2 clinical trial; Finalizing site enrollment with up to six institutions with ‘first patient, first dose’ expected in the second quarter of 2024; Created Shuttle Diagnostics; Entered into an exclusive agreement to license certain intellectual property from Georgetown University to advance the Company’s predictive biomarker program; Obtained an exclusive license for PSMA-B intellectual property for advancing research into diagnostic and therapeutic applications of metastatic prostate cancer; At March 31, 2024, Shuttle Pharma’s cash balance was approximately $4.2 million
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH:
- Shuttle Pharma Provides First Quarter 2024 Corporate Update
- Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1×1 Meetings on Thursday, May 2, 2024
- Shuttle Pharmaceuticals files to sell subscription rights to buy $4.5M in units
- Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024